BASKING RIDGE, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG) announced today that Mark C. Mirken has been elected President and Chief Operating Officer of Millennium and its subsidiary Millennium Biotechnologies, Inc. Mr. Mirken brings more that 18 years of combined senior level management, product development and marketing expertise to Millennium. Mr. Mirken was President and Chief Operating Officer of TurboChef Technologies, Inc. (OVEN) where he was responsible for overseeing the global expansion of the company's product line. Under his direction the TurboChef line of products expanded both domestically and internationally serving such global companies as Starbucks, Subway and HMS Host. Earlier, Mr. Mirken was the Senior Vice President of Development for The Trump Organization. He holds a bachelor's degree in political science from the University of North Carolina and received his JD from the University of North Carolina.
Jerry Swon, CEO of Millennium, commented, "Mark Mirken has a proven track record as a senior level executive in the public arena and will be instrumental in helping to take Millennium to the next level. His success and accomplishments while serving as the Chief Operating Officer of TurboChef Technologies Inc. should add significant depth to our team. Mark was the catalyst for the initial sales and business relationships between TurboChef, Subway, Starbucks and numerous other global accounts which subsequently built TurboChef in to a world-wide brand. Based on Mark's success in establishing these relationships annual sales grew materially, ultimately driving shareholder value. We see his time tested skills and global relationships as key elements in developing and commercially exploiting our products across a very broad and lucrative spectrum. He has an excellent reputation in the financial markets having spent the last two years consulting for numerous funds including Fidelity, KKR and Northpointe Capital. We are extremely pleased to have Mark join and our team and help lead the charge of our expansion."
Mark Mirken, stated, "I have evaluated numerous opportunities over the past years and I am clearly convinced that Millennium presents a compelling opportunity. The unique product portfolio should provide incredible growth opportunities across a broad range of channels, both clinical and athletic. The emerging use of Resurgex's(R) patented targeted nutritional supplements technology to provide sustainable cellular improvement, which has been clinically demonstrated, has only begun to take shape. I believe the Company has an incredible future as the commercialization of its product portfolio expeditiously unfolds, clearly we are just at the tip of the implementation iceberg."
About Millennium Biotechnologies, Inc.: Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX(R), RESURGEX Plus(R), and RESURGEX Select(R), are designed to assist in reducing fatigue and oxidative stress, maintaining lean muscle and immune support in immunocompromised conditions.
Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTC Bulletin Board: MBTG). For more information about Millennium Biotechnologies, please contact Jerry Swon, Chief Executive Officer, at email@example.com or call (908) 604-2500. For more information about the Resurgex line of products visit http://www.resurgex.com.
This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and Resurgex Plus and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
|SOURCE Millennium Biotechnologies Group, Inc.|
Copyright©2007 PR Newswire.
All rights reserved